Yüklüyor......

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era

Classical Hodgkin lymphoma (HL) relapses after or is refractory to upfront multiagent chemotherapy in 20%–30% of patients. Effective salvage therapy for relapsed or refractory HL is limited, and advancements are needed. Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate, has demonstrated...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hematology Am Soc Hematol Educ Program
Asıl Yazarlar: Graf, Solomon A., Gopal, Ajay K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418463/
https://ncbi.nlm.nih.gov/pubmed/25696848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/asheducation-2014.1.151
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!